<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00880997</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-18197-4</org_study_id>
    <secondary_id>P50DA018197-04</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT00880997</nct_id>
  </id_info>
  <brief_title>The Efficacy of Doxazosin for Cocaine Users</brief_title>
  <official_title>Doxazosin, An Alpha-1 Adrenergic Antagonist, for Cocaine Dependence: Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Doxazosin, an alpha 1-adrenergic receptor, may play an important role in cocaine addiction in
      humans. This study will evaluate the effectiveness of doxazosin in preventing drug relapse
      among cocaine dependent participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The NE system, especially the alpha 1-adrenergic receptor, may play an important role in
      cocaine addiction in humans. The results of this study will provide medical safety data on
      the duration of the induction schedule that will be optimal for attaining our target dose of
      8 mg doxazosin daily and will guide future pharmacotherapy trials using Doxazosin or related
      alpha 1 receptor antagonists for cocaine addiction.

      This 17-week double-blind, placebo controlled clinical trial includes a 13 week medication
      trial (weeks 1-13) and up to 4 week washout period(weeks 14-17). Qualifying subjects will be
      randomized to receive Doxazosin 8 mg/day, or placebo during the study participation.

      Medication induction will occur at a rate of 2mg/week until 8mg/day target dose is achieved
      as follows:

        1. Dox-Fast Group: Defined as participants reaching the target dose after a 4-week
           titration period. Participants will be stabilized on doxazosin or placebo over weeks
           4-13 (for Dox-Fast group)

        2. Dox-Slow Group: Defined as participants reaching the target dose after an 8-week
           titration period. Participants will be stabilized on doxazosin or placebo over weeks
           8-13 (for Dox-Slow group)

      Both groups will be tapered off doxazosin or placebo over study weeks 14-17.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cocaine Negative Urines</measure>
    <time_frame>throughout the study - up to 17 weeks</time_frame>
    <description>cocaine urine toxicology samples were obtained thrice weekly and tested for the presence of the cocaine metabolite, benzoylecgonine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weeks of Abstinence</measure>
    <time_frame>throughout the study - up to 17 weeks</time_frame>
    <description>Percentage of participants achieving 2 or more consecutive weeks of abstinence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure># of Participants That Completed the Study</measure>
    <time_frame>throughout the study - up to 17 weeks</time_frame>
    <description>Retention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>throughout study - upto 17 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>Doxazosin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medication induction occurred at a rate of 2mg/week until 8mg/day target dose was achieved as follows:
Dox-Fast Group: Defined as participants reaching the target dose after a 4-week titration period. Participants were stabilized on doxazosin or placebo over weeks 4-13 (for Dox-Fast group)
Dox-Slow Group: Defined as participants reaching the target dose after an 8-week titration period. Participants were stabilized on doxazosin or placebo over weeks 8-13 (for Dox-Slow group)
Both groups were tapered off doxazosin or placebo over study weeks 14-17.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A sugar pill to mimic the experiment drug, doxazosin, will be administered in the same manner as the experimental drug through the study duration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxazosin</intervention_name>
    <description>Medication induction occurred at a rate of 2mg/week until 8mg/day target dose was achieved as follows:
Dox-Fast Group: Defined as participants reaching the target dose after a 4-week titration period. Participants were stabilized on doxazosin or placebo over weeks 4-13 (for Dox-Fast group)
Dox-Slow Group: Defined as participants reaching the target dose after an 8-week titration period. Participants were stabilized on doxazosin or placebo over weeks 8-13 (for Dox-Slow group)
Both doxazosin groups will be tapered off doxazosin or placebo over study weeks 14-17.</description>
    <arm_group_label>Doxazosin</arm_group_label>
    <other_name>Cardura (Doxazosin Mesylate)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will be administered a sugar pill to mimic the doxazosin active medication with administration being the same as the active medication.</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>sugarpills ( Capsules)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets DSM-IV diagnosis criteria for cocaine dependence, as determined by self-reported
             use of cocaine at least once weekly for at least 1 month prior to study entry; a
             positive urine test for cocaine; and a score greater than 3 on the Severity of
             Dependence Scale

          -  If female, willing to use contraception throughout the study

        Exclusion Criteria:

          -  Meets DSM-IV diagnosis criteria for dependence on any drugs other than cocaine, or
             tobacco

          -  Current major psychiatric illness, including schizophrenia, bipolar disorder, or other
             psychotic disorder

          -  Current suicidal or homicidal ideation

          -  Current use of a prescribed psychotropic medication that cannot be discontinued

          -  History of or current major medical illness, including major heart, kidney, endocrine,
             or liver disorder; abnormal liver function (SGOT or SGPT levels three times greater
             than normal); or high blood pressure or low blood pressure

          -  High risk factor for heart disease, seizure disorders, or any illness for which
             disulfiram or methadone treatment would be inadvisable

          -  Currently taking metronidazole or clotrimazole

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas R Kosten, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baylor College of Medicine - Michael E. DeBakey VA Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 13, 2009</study_first_submitted>
  <study_first_submitted_qc>April 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2009</study_first_posted>
  <results_first_submitted>February 4, 2017</results_first_submitted>
  <results_first_submitted_qc>August 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 22, 2019</results_first_posted>
  <last_update_submitted>August 8, 2019</last_update_submitted>
  <last_update_submitted_qc>August 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Thomas R. Kosten, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Cocaine Dependence</keyword>
  <keyword>Substance Related Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxazosin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Thirty-five subjects were randomized into the study, with 30 subjects returning and receiving at least one dose of medication.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Doxazosin Fast</title>
          <description>Participantsreaching the target dose after a 4-week titration period</description>
        </group>
        <group group_id="P2">
          <title>Doxazosin Slow</title>
          <description>Participants reaching the target dose after an 8-week titration period</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Matching placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Cocaine dependent individuals = 17; Placebo = 13; 5 lost to followup. During analysis, an additional 2 individuals were dropped due from analyses due to invalidated data.</population>
      <group_list>
        <group group_id="B1">
          <title>Doxazosin Slow Titration</title>
          <description>Medication induction occurred at a rate of 2mg/week until 8mg/day target dose was achieved as follows:
Dox-Slow Group: Participants reaching the target dose after an 8-week titration period. Participants were stabilized on doxazosin over weeks 8–13.
Participants were tapered off doxazosin or placebo over study weeks 14–17.</description>
        </group>
        <group group_id="B2">
          <title>Doxazosin Fast Titration</title>
          <description>Medication induction occurred at a rate of 2mg/week until 8mg/day target dose was achieved as follows:
Dox-Fast Group: Participants reaching the target dose after a 4-week titration period. Participants were stabilized on doxazosin over weeks 4–13.
Participants were tapered off doxazosin or placebo over study weeks 14–17.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Participants received matched placebo during weeks 1–13.
Participants were tapered off placebo over study weeks 14–17.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="13"/>
            <count group_id="B4" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.1" spread="7.4"/>
                    <measurement group_id="B2" value="47.4" spread="11.0"/>
                    <measurement group_id="B3" value="48.2" spread="8.6"/>
                    <measurement group_id="B4" value="48" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Employment</title>
          <description>Employed over the past 3 years</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol use - past 30 days</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.63" spread="3.77"/>
                    <measurement group_id="B2" value="10.11" spread="9.55"/>
                    <measurement group_id="B3" value="7.85" spread="9.89"/>
                    <measurement group_id="B4" value="8.5" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cocaine use - past 30 days</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.13" spread="8.90"/>
                    <measurement group_id="B2" value="7.89" spread="6.92"/>
                    <measurement group_id="B3" value="14.85" spread="10.25"/>
                    <measurement group_id="B4" value="15" spread="8.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cocaine Negative Urines</title>
        <description>cocaine urine toxicology samples were obtained thrice weekly and tested for the presence of the cocaine metabolite, benzoylecgonine</description>
        <time_frame>throughout the study - up to 17 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DOX-slow Group</title>
            <description>Participants reaching the target dose after an 8-week titration period are labeled as the DOX slow group. Participants were stabilized on doxazosin over weeks 8–13 and then tapered off doxazosin over study weeks 14–17.</description>
          </group>
          <group group_id="O2">
            <title>DOX-fast Group</title>
            <description>Participants reaching the target dose after a 4-week period are labeled as the DOX-fast group. Participants were stabilized on doxazosin over weeks 4–13 and then tapered off doxazosin over study weeks 14–17.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants took placebo during weeks 1–17.</description>
          </group>
        </group_list>
        <measure>
          <title>Cocaine Negative Urines</title>
          <description>cocaine urine toxicology samples were obtained thrice weekly and tested for the presence of the cocaine metabolite, benzoylecgonine</description>
          <units>percentage of cocaine-negative urines</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weeks of Abstinence</title>
        <description>Percentage of participants achieving 2 or more consecutive weeks of abstinence</description>
        <time_frame>throughout the study - up to 17 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DOX-slow Group</title>
            <description>Participants reaching the target dose after an 8-week titration period are labeled as the DOX slow group. Participants were stabilized on doxazosin over weeks 8–13 and then tapered off doxazosin over study weeks 14–17.</description>
          </group>
          <group group_id="O2">
            <title>DOX-fast Group</title>
            <description>Participants reaching the target dose after a 4-week period are labeled as the DOX-fast group. Participants were stabilized on doxazosin over weeks 4–13 and then tapered off doxazosin over study weeks 14–17.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants took placebo during weeks 1–17.</description>
          </group>
        </group_list>
        <measure>
          <title>Weeks of Abstinence</title>
          <description>Percentage of participants achieving 2 or more consecutive weeks of abstinence</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title># of Participants That Completed the Study</title>
        <description>Retention</description>
        <time_frame>throughout the study - up to 17 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DOX-slow Group</title>
            <description>Participants reaching the target dose after an 8-week titration period are labeled as the DOX slow group. Participants were stabilized on doxazosin over weeks 8–13 and then tapered off doxazosin over study weeks 14–17.</description>
          </group>
          <group group_id="O2">
            <title>DOX-fast Group</title>
            <description>Participants reaching the target dose after a 4-week period are labeled as the DOX-fast group. Participants were stabilized on doxazosin over weeks 4–13 and then tapered off doxazosin over study weeks 14–17.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants took placebo during weeks 1–17.</description>
          </group>
        </group_list>
        <measure>
          <title># of Participants That Completed the Study</title>
          <description>Retention</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <time_frame>throughout study - upto 17 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DOX-slow Group</title>
            <description>Participants reaching the target dose after an 8-week titration period are labeled as the DOX slow group. Participants were stabilized on doxazosin over weeks 8–13 and then tapered off doxazosin over study weeks 14–17.</description>
          </group>
          <group group_id="O2">
            <title>DOX-fast Group</title>
            <description>Participants reaching the target dose after a 4-week period are labeled as the DOX-fast group. Participants were stabilized on doxazosin over weeks 4–13 and then tapered off doxazosin over study weeks 14–17.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants took placebo during weeks 1–17.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected over the entire study duration for all patients, up to 17 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dox-Slow Group</title>
          <description>Defined as participants reaching the target dose after an 8-week titration period. Participants were stabilized on doxazosin or placebo over weeks 8–13 (for Dox-Slow group)</description>
        </group>
        <group group_id="E2">
          <title>Dox-Fast Group:</title>
          <description>Defined as participants reaching the target dose after a 4-week titration period. Participants were stabilized on doxazosin or placebo over weeks 4–13 (for Dox-Fast group)</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>A sugar pill to mimic the experiment drug, doxazosin, will be administered in the same manner as the experimental drug through the study duration.
Placebo: Placebo daily dosing</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Dizinness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Initially the study randomized subjects into 2 conditions (placebo/DOX). After the observation that rapid titration was safe, a DOX-fast group was created. This did not allow for early participants to be randomized to the rapid titration condition.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Thomas Kosten, MD</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>713-794-7032</phone>
      <email>kosten@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

